Cargando…

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia

The objective was to compare the clinical efficacy of cefoperazone-sulbactam with piperacillin-tazobactam in the treatment of severe community-acquired pneumonia (SCAP). The retrospective study was conducted from March 1, 2018 to May 30, 2019. Clinical outcomes were compared for patients who receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Chih-Cheng, Chen, Wei-Chih, Kuo, Li-Kuo, Wang, Yao-Tung, Fu, Pin-Kuei, Ku, Shih-Chi, Fang, Wen-Feng, Chen, Chin-Ming, Tu, Chih-Yen, Cheng, Wen-Chien, Chen, Chia-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	6700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344575/ https://www.ncbi.nlm.nih.gov/pubmed/37443505 http://dx.doi.org/10.1097/MD.0000000000034284

Ejemplares similares

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Chen, Chia-Hung, et al.
Publicado: (2021)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
por: Wang, Xueting, et al.
Publicado: (2023)

Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients
por: Chen, Yue, et al.
Publicado: (2021)

Cross-reactivity between piperacillin–tazobactam and cefoperazone–sulbactam in drug-induced immune thrombocytopenia
por: He, Xiaoyan, et al.
Publicado: (2023)

Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients
por: Wang, Xiao-Xia, et al.
Publicado: (2021)

Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Enterobacteriaceae Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation
por: Yang, Fengzhen, et al.
Publicado: (2022)

Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products
por: Sheu, Ming-Jen, et al.
Publicado: (2020)

Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease
por: Chao, Chien-Ming, et al.
Publicado: (2022)

Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience
por: Chen, Chia-Hung, et al.
Publicado: (2017)

The prognosis in extremely elderly patients receiving orotracheal intubation and mechanical ventilation after planned extubation
por: Cheng, Ai-Chin, et al.
Publicado: (2020)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
por: Islek, Ismail, et al.
Publicado: (2003)

Cefoperazone-Sulbactam Associated Refractory Seizures
por: Chovatiya, Harshad, et al.
Publicado: (2021)

Cefoperazone/sulbactam-induced hemolytic anemia
por: Sun, XM, et al.
Publicado: (2023)

Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis
por: Lan, Shao-Huan, et al.
Publicado: (2020)

Significance of the Modified NUTRIC Score for Predicting Clinical Outcomes in Patients with Severe Community-Acquired Pneumonia
por: Tseng, Chia-Cheng, et al.
Publicado: (2021)

Case Report: Drug-Induced Immune Haemolytic Anaemia Caused by Cefoperazone-Tazobactam/ Sulbactam Combination Therapy
por: Wu, Yuanjun, et al.
Publicado: (2021)

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder
por: Miao, Wan, et al.
Publicado: (2023)

The safety and efficacy of alfentanil-based induction in bronchoscopy sedation: A randomized, double-blind, controlled trial
por: Hsieh, Chung-Hsing, et al.
Publicado: (2016)

Pneumoconiosis Increases the Risk of Peripheral Arterial Disease: A Nationwide Population-Based Study
por: Shen, Chih-Hao, et al.
Publicado: (2015)

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam
por: Zhou, Ling, et al.
Publicado: (2019)

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis
por: Jiang, Weizhong, et al.
Publicado: (2023)

Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study
por: Lee, Ming-Chia, et al.
Publicado: (2015)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
por: Tang, Xi-kang, et al.
Publicado: (2022)

Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam
por: Qu, Yan-Jing, et al.
Publicado: (2016)

Clinic image surveillance reduces mortality in patients with primary hepato-gastrointestinal cancer who develop second primary lung cancer: A STROBE-compliant retrospective study
por: Huang, Hung-Yu, et al.
Publicado: (2020)

Exercise-Induced Changes in Exhaled NO Differentiates Asthma With or Without Fixed Airway Obstruction From COPD With Dynamic Hyperinflation
por: Huang, Shu-Yi, et al.
Publicado: (2016)

In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria
por: Xiao, Shunian, et al.
Publicado: (2021)

Pulmonary rehabilitation coupled with negative pressure ventilation decreases decline in lung function, hospitalizations, and medical cost in COPD: A 5-year study
por: Huang, Hung-Yu, et al.
Publicado: (2016)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Case report: Cefoperazone-sulbactam induced Kounis syndrome and cardiogenic shock
por: Ding, Peng, et al.
Publicado: (2022)

Retracted: In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy
por: Wang, Qiang, et al.
Publicado: (2015)

IgG4-related lung disease presenting as interstitial lung disease with bronchiolitis: A case report
por: Chen, Chiu-Fan, et al.
Publicado: (2017)

Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
por: ÖZYILKAN, Özgür, et al.
Publicado: (1999)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3sptk1humlcm57g5n5i69pido3